| Primary |
| Drug Use For Unknown Indication |
21.1% |
| Product Used For Unknown Indication |
15.9% |
| Hypertension |
9.0% |
| Prophylaxis |
6.2% |
| Headache |
5.0% |
| Antiplatelet Therapy |
4.3% |
| Coronary Artery Disease |
4.2% |
| Cardiovascular Event Prophylaxis |
4.0% |
| Cardiac Failure |
3.5% |
| Cardiac Failure Chronic |
3.1% |
| Acute Coronary Syndrome |
2.9% |
| Cerebrovascular Accident |
2.8% |
| Myocardial Infarction |
2.6% |
| Atrial Fibrillation |
2.3% |
| Chronic Obstructive Pulmonary Disease |
2.3% |
| Juvenile Idiopathic Arthritis |
2.3% |
| Thrombosis Prophylaxis |
2.3% |
| Depression |
2.1% |
| Pain |
2.1% |
| Systemic Lupus Erythematosus |
2.1% |
|
| Therapeutic Agent Toxicity |
15.2% |
| Gastrointestinal Haemorrhage |
12.2% |
| Vomiting |
7.3% |
| Wrong Drug Administered |
6.7% |
| Gastric Haemorrhage |
4.9% |
| Toxicity To Various Agents |
4.9% |
| Ulcer Haemorrhage |
4.9% |
| Cerebral Haemorrhage |
4.3% |
| Thrombosis |
4.3% |
| Ulcer |
4.3% |
| Incorrect Drug Administration Duration |
3.7% |
| Rectal Haemorrhage |
3.7% |
| Thrombocytopenia |
3.7% |
| Hypersensitivity |
3.0% |
| Pain |
3.0% |
| Subdural Haematoma |
3.0% |
| Urinary Tract Infection |
3.0% |
| Urticaria |
3.0% |
| Haemorrhage |
2.4% |
| Loss Of Consciousness |
2.4% |
|
| Secondary |
| Product Used For Unknown Indication |
26.5% |
| Drug Use For Unknown Indication |
15.9% |
| Hypertension |
8.7% |
| Pain |
5.1% |
| Depression |
4.3% |
| Atrial Fibrillation |
4.2% |
| Anticoagulant Therapy |
3.5% |
| Antiplatelet Therapy |
3.5% |
| Diabetes Mellitus |
3.0% |
| Thrombosis Prophylaxis |
3.0% |
| Percutaneous Coronary Intervention |
2.9% |
| Coronary Artery Disease |
2.6% |
| Prophylaxis Against Renal Transplant Rejection |
2.4% |
| Prophylaxis |
2.2% |
| Acute Myocardial Infarction |
2.2% |
| Acute Coronary Syndrome |
2.0% |
| Cerebrovascular Accident Prophylaxis |
2.0% |
| Type 2 Diabetes Mellitus |
2.0% |
| Myocardial Infarction |
2.0% |
| Pyrexia |
1.8% |
|
| Vomiting |
9.8% |
| Drug Hypersensitivity |
9.5% |
| Gastrointestinal Haemorrhage |
7.5% |
| Renal Failure Acute |
6.4% |
| Thrombosis In Device |
6.4% |
| Rectal Haemorrhage |
5.4% |
| Urticaria |
5.4% |
| Suicide Attempt |
4.7% |
| Toxic Epidermal Necrolysis |
4.7% |
| Vision Blurred |
4.7% |
| Completed Suicide |
4.4% |
| Fibromyalgia |
3.7% |
| Weight Decreased |
3.7% |
| Haemoglobin Decreased |
3.4% |
| Haemorrhage |
3.4% |
| Restless Legs Syndrome |
3.4% |
| Subdural Haematoma |
3.4% |
| Thrombocytopenia |
3.4% |
| Upper Gastrointestinal Haemorrhage |
3.4% |
| Syncope |
3.1% |
|
| Concomitant |
| Hypertension |
17.9% |
| Product Used For Unknown Indication |
14.9% |
| Drug Use For Unknown Indication |
11.0% |
| Smoking Cessation Therapy |
7.5% |
| Blood Cholesterol Increased |
5.8% |
| Diabetes Mellitus |
5.0% |
| Cardiac Disorder |
4.5% |
| Pain |
4.3% |
| Depression |
4.0% |
| Rheumatoid Arthritis |
3.4% |
| Prophylaxis |
3.4% |
| Hormone Replacement Therapy |
3.3% |
| Type 2 Diabetes Mellitus |
2.4% |
| Atrial Fibrillation |
2.2% |
| Anxiety |
2.0% |
| Coronary Artery Disease |
2.0% |
| Gastrooesophageal Reflux Disease |
1.9% |
| Anticoagulant Therapy |
1.6% |
| Osteoarthritis |
1.5% |
| Arthritis |
1.4% |
|
| Nausea |
11.2% |
| Vomiting |
11.2% |
| Drug Ineffective |
8.7% |
| Weight Increased |
8.3% |
| Weight Decreased |
6.7% |
| Syncope |
4.6% |
| Renal Failure Acute |
4.4% |
| Somnolence |
4.3% |
| Myalgia |
4.1% |
| Myocardial Infarction |
4.0% |
| Breast Cancer Female |
3.8% |
| Pain In Extremity |
3.6% |
| Pain |
3.5% |
| Vision Blurred |
3.3% |
| Tremor |
3.3% |
| Death |
3.2% |
| Urinary Tract Infection |
3.1% |
| Pneumonia |
3.0% |
| Malaise |
2.8% |
| Insomnia |
2.7% |
|
| Interacting |
| Product Used For Unknown Indication |
23.4% |
| Hypertension |
13.6% |
| Cerebrovascular Accident Prophylaxis |
10.6% |
| Atrial Fibrillation |
10.4% |
| Pain |
8.0% |
| Coronary Artery Disease |
4.8% |
| Thrombosis Prophylaxis |
2.9% |
| Cardiac Failure |
2.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.7% |
| Diabetes Mellitus |
2.4% |
| Hyperlipidaemia |
2.4% |
| Type 2 Diabetes Mellitus |
2.4% |
| Blood Pressure |
2.1% |
| Depression |
1.9% |
| Stent Placement |
1.9% |
| Acute Coronary Syndrome |
1.6% |
| Asthma |
1.6% |
| Atrial Flutter |
1.6% |
| Cerebrovascular Accident |
1.6% |
| Fallot's Tetralogy |
1.6% |
|
| Drug Interaction |
13.8% |
| Renal Failure Acute |
13.8% |
| Gastrointestinal Haemorrhage |
11.3% |
| Upper Gastrointestinal Haemorrhage |
7.5% |
| Lower Gastrointestinal Haemorrhage |
5.0% |
| Pancytopenia |
5.0% |
| Product Quality Issue |
5.0% |
| Haemorrhage |
3.8% |
| International Normalised Ratio Increased |
3.8% |
| Rhabdomyolysis |
3.8% |
| Thrombosis In Device |
3.8% |
| Weight Decreased |
3.8% |
| Diarrhoea |
2.5% |
| Disseminated Intravascular Coagulation |
2.5% |
| Hyperglycaemia |
2.5% |
| Hypertension |
2.5% |
| Hypotension |
2.5% |
| Nausea |
2.5% |
| Procedural Haemorrhage |
2.5% |
| Rectal Ulcer Haemorrhage |
2.5% |
|
